MTRI

13.66510.36%
BR

Brett R. Hagen

CAO & Senior VP of Finance

Mr. Brett R. Hagen is Chief Accounting Officer & Senior Vice President of Finance of Mentari Therapeutics, Inc. Mr. Hagen had been Chief Accounting Officer of Kalaris Therapeutics, Inc. since March 19, 2025 until July 27, 2026 and served as its Principal Accounting Officer until July 27, 2026 as well as its Principal Financial Officer since April 14, 2026 until July 27, 2026. He had been Principal Financial Officer of Kalaris Therapeutics, Inc. since March 19, 2025 until November 3, 2025 as well as its Senior VP of Finance until November 3, 2025. He has served as Chief Accounting Officer of Allovir, Inc. since January 2019. Prior to joining AlloVir, from February 2018 to August 2018, he served as Senior Director Finance and Accounting at Eloxx Pharmaceuticals, Inc. Mr. Hagen was Principal Accounting Officer and Vice President of Finance at Proteostasis Therapeutics, Inc. since May2016 until December 2017. Mr. Hagen served as Principal Financial Officer and Controller of Proteostasis Therapeutics, Inc. since March 8, 2017 and May 2016 respectively. Mr. Hagen served as Interim Treasurer of Proteostasis Therapeutics, Inc. since February 10, 2017 and served as its Interim Chief Financial Officer from February 10, 2017 to March 8, 2017. He served as a Controller for BIND Therapeutics, Inc. He served as Vice President of Finance/Segment Controller of Boston Private Financial Holdings. He served as Manager of SEC Financial Reporting and Technical Account of The Princeton Review. He served as Controller of BioProcessors Corporation. He held a number of positions at PricewaterhouseCoopers LLP. Mr. Hagen received a B.A. from University of Minnesota, a Master in Accountancy from Wright State University and a M.S. in Finance from Suffolk University.

Positions